Please assess the completion status of the following clinical trial:

Trial Title: Effects of Transdermal Testosterone and/or Monthly Vitamin D on Fall Risk in Pre--frail Hypogonadal Seniors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Men with documented total testosterone levels \< 11.30 nmol/l~2. Able to come to the study centre (Community-dwelling or institutionalized)~3. Age 65+ years~4. At a higher risk for falling~5. Body mass index \> 18.0 and \< 35.0 kg/m2~6. Understands German in reading and writing plus able to read, understand, and complete questionnaires and tests.~7. Willingness to limit additional vitamin D3 intake to a maximum of 800 IU per day~8. Willingness to limit calcium supplement intake to 500 mg/day~9. Willingness to stop active vitamin D metabolites~10. Willingness to forgo any additional use/application of testosterone products for the duration of the trial.~11. Participant understands the study procedures, alternative treatments available and risks involved with the study and voluntarily agrees to participate by giving a written informed consent.~12. Participant meets the routine clinical laboratory safety screening tests performed at screening visit.~13. Participant is able and willing to perform all study tests, attend all required office visits, and provide blood and urine samples.~14. Participant is able to apply the testosterone/placebo gel and is able to drink the vitamin D/placebo solution.~15. Participant is mentally competent (judicious) defined by having score \> 24 on the Folstein's mini mental state examination (MMSE) at the screening visit.~Exclusion Criteria:~1. Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product~2. Treatment with vitamin K-antagonists, insulin, adrenocorticotropic hormone (ACTH), corticosteroid (\>5mg/d)~3. Elevated (≥ 4.0 ng/ml) prostate-specific antigen levels (at screening) and/or palpable signs of prostate cancer~4. Palpable signs of breast-cancer~5. Haemoglobin ≤ 100 g/l~6. Haematocrit ≥ 0.50 L/L~7. Liver function values (alanine aminotransferase, aspartate aminotransferase, Gamma-glutamyl transferase, alkaline phosphatase) more than 3 times the upper limit of normal.~8. Consumption of \>800 IU vitamin D on any day in the 6 months prior to enrolment. Provision: a person can be enrolled as soon as the mean intake in the last 6 months and since the last dose is ≤ 800 IU.~9. Elevated serum calcium ≥ 2.60 mmol/l (adjusted for albumin )~10. Estimated (Cockcroft and Gault formula ) creatinine clearance ≤ 30 ml/min~11. Severe visual or hearing impairment~12. History of cancer \< 5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer~13. Myocardial infarction in the last 3 months, unstable angina pectoris and/or exertional dyspnoea \>=NYHA III~14. Treatment worthy but untreated sleep apnoea or chronic (obstructive) pulmonary disease, epilepsy~15. Significant end-stage disease, i.e. genitourinary, cardiovascular, hepatic, renal, endocrine, hematologic, psychiatric, or pulmonary disease, which, in the opinion of the investigator, may pose a high risk to the patient or impair the patient's ability to complete the trial or confound the results~16. Uncontrolled hypertension (blood pressure mm Hg ≥ 180 systolic or ≥ 110 diastolic)~17. Alcohol abuse or alcoholic disease~18. Participation in another interventional research trial within the last 6 months prior to screening~19. Severe gait impairment, e.g. due to Parkinson's disease or hemiplegia~20. Previous enrolment into the current study~21. Enrolment of the investigator, his/her family members, employees and other dependent persons

- Gender: MALE
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Testosterone + Vitamin D (Type: ACTIVE_COMPARATOR): Testosterone, transdermal gel, 75 mg, once per day, for 12 months AND Colecalciferol, oral drink solution, 24000 IU, once per month, for 12 months
- Testosterone + Placebo (Type: ACTIVE_COMPARATOR): Testosterone, transdermal gel, 75 mg, once per day, for 12 months AND Placebo: Colecalciferol, oral drink solution, 0 IU, once per month, for 12 months
- Placebo + Vitamin D (Type: ACTIVE_COMPARATOR): Placebo: Testosterone, transdermal gel, 0 mg, once per day, for 12 months AND Colecalciferol, oral drink solution, 24000 IU, once per month, for 12 months
- Control (Type: PLACEBO_COMPARATOR): Placebo: Testosterone, transdermal gel, 0 mg, once per day, for 12 months AND Placebo: Colecalciferol, oral drink solution, 0 IU, once per month, for 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues